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Background: This randomized, double-blind, multicenter study 
 evaluated sunitinib plus erlotinib versus placebo plus erlotinib. 
Subjects with advanced non–small-cell lung cancer had received 
prior treatment with a platinum-based regimen. Here, we report 
safety, pharmacokinetics, and antitumor activity of the combination 
of sunitinib and erlotinib.
Methods: Lead-in subjects in this phase II study received sunitinib 
37.5 mg/d and erlotinib 150 mg/d. Safety, including dose-limiting 
toxicities (DLTs, cohort 1 only), pharmacokinetic profiles, and anti-
tumor activity were investigated (cohorts 1 and 2).
Results: Thirty patients were evaluated. The combination of sunitinib 
and erlotinib was tolerable. Diarrhea (76.9%), fatigue (61.5%), and 
decreased appetite (53.8%) were the most frequent adverse events in 
cohort 1; and diarrhea (52.9%) and rash (41.2%) were the most fre-
quent adverse events in cohort 2. DLTs were observed (fatigue, n = 2 
and paronychial inflammation, n = 1) in three of 13 patients evaluated 
for DLTs. Geometric mean ratios for the maximum plasma concen-
tration (C
max
) and area under plasma concentration–time profile from 
time 0 to 24 hours of erlotinib with and without sunitinib were 1.05 
and 1.03, respectively. Corresponding values for sunitinib with and 
without erlotinib were 0.62 and 0.62 for sunitinib, 2.13 and 2.07 for 
SU12662; and 0.81 and 0.79 for total drug. Three patients experienced 
partial response as per response evaluation criteria in solid tumor.
Conclusion: A dosage of sunitinib 37.5 mg/d concurrently with erlo-
tinib 150 mg/d was tolerable and established the recommended com-
binatorial dose in subjects with platinum-refractory non–small-cell 
lung cancer. Coadministration of sunitinib with erlotinib does not 
affect the pharmacokinetics of erlotinib, but may result in decreased 
exposure to sunitinib.
Key Words: Non–small-cell lung cancer, Sunitinib, Erlotinib, Safety, 
Pharmacokinetics.
(J Thorac Oncol. 2012;7: 1406–1416)
Lung cancer is the leading cause of cancer-related death worldwide.1,2 Non–small-cell lung cancer (NSCLC) 
accounts for approximately 85% of cases, and most patients 
present with advanced/metastatic disease, for which there 
are no known curative therapies.3,4 Although platinum-based 
doublet chemotherapy often comprises first-line treatment for 
advanced NSCLC,5–7 erlotinib, a molecularly targeted agent 
directed against epidermal growth factor receptor (EGFR), 
has demonstrated improved survival.8 It is commonly used 
in the second-line treatment setting, and may be most active 
against tumors with activating EGFR mutations. Sunitinib 
malate is an oral receptor tyrosine kinase (RTK) inhibitor 
with activity against vascular endothelial growth factor recep-
tors (VEGFRs; −1, −2, and −3), platelet-derived growth fac-
tor receptors (PDGFRs; −α and −β), stem-cell factor receptor 
(KIT), FMS-like tyrosine kinase 3, colony-stimulating fac-
tor 1 receptor, and glial cell-line–derived neurotrophic fac-
tor receptor (REarranged during Transfection).9–12 These 
RTKs are linked to cellular signaling pathways that regulate 
processes critical for tumor development and metastasis, 
including angiogenesis, cell proliferation, and cell survival.13 
Sunitinib is approved worldwide for the treatment of meta-
static renal cell carcinoma, gastrointestinal stromal tumor 
after progression on, or intolerance to imatinib treatment,14 
and pancreatic neuroendocrine tumor.15 In a phase II study of 
refractory NSCLC, sunitinib, given on either an intermittent 
or continuous daily-dosing schedule, had promising antitumor 
activity and was tolerable.16,17
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Although targeting one tumor signaling pathway may be 
effective, simultaneous targeting of several may result in greater 
therapeutic benefit, as these alternative signaling pathways may 
serve as mechanisms of resistance for a particular therapy.18 
Thus, concomitant inhibition of VEGFR, PDGFR, and EGFR 
via sunitinib plus erlotinib may improve clinical outcome 
in NSCLC via several mechanisms. Examples of potential 
antiangiogenic effects include inhi bition of VEGFR-mediated 
endothelial cell proliferation and migration, inhibition of PDGF 
signaling pathways that are integral to the growth and survival of 
vascular smooth muscle cells and pericytes, and downregulation 
of proangiogenic growth factors regulated by EGFR.19–21 Direct 
antitumor effects include those mediated by inhibition of EGFR 
and PDGFR autocrine signaling pathways.21,22 The potential 
of a novel treatment strategy for NSCLC based on combined 
targeted inhibition of VEGFR–PDGFR–EGFR is supported 
by data from NSCLC xenograft models that suggest sunitinib 
may augment the antitumor activity of erlotinib (Pfizer Inc., 
unpublished data on file).
We investigated sunitinib combined with erlotinib in a 
lead-in population of patients with advanced NSCLC, before 
starting the randomized phase II portion of the study. The 
objective of the lead-in phase was to confirm the dose and 
schedule of sunitinib and erlotinib when administered in com-
bination, and to assess the tolerability of the combination. 
Here, we report safety, pharmacokinetics, and activity of this 
combination from the lead-in cohorts.
PATIENTS AND METHODS
Patients
Patients were randomized between June 2006 and June 
2009. The study population comprised male and female patients 
aged 18 years or older with histologically confirmed NSCLC 
that was either locally advanced (stage IIIB with malignant effu-
sion) or metastatic (stage IV). Patients were included if they 
had prior treatment with one or two chemotherapy regimens, 
including a platinum-based regimen; evidence of unidimension-
ally measurable disease as per Response Evaluation Criteria in 
Solid Tumors (RECIST, version 1.0);23 radiographic evidence 
of disease progression; Eastern Cooperative Oncology Group 
(ECOG) performance status of 0 or 1; resolution of all acute toxic 
effects of prior therapy or surgical procedures to National Cancer 
Institute Common Terminology Criteria for Adverse Events 
(NCI CTCAE) version 3.0 grade 1 or lower; adequate lung func-
tion defined as dyspnea of NCI CTCAE grade 2 or lower; and 
adequate liver, renal, and hematologic function. Patients were 
excluded if they had prior treatment with any RTK inhibitor, 
VEGF inhibitor (with the exception of bevacizumab), or other 
angiogenic inhibitors; a history of or current brain metastases, 
spinal cord compression, or carcinomatous meningitis; hyperten-
sion that was not controlled by medication; evidence of hemop-
tysis for less than 4 weeks before starting study treatment (>5 
ml blood per episode or >10 ml blood per 24-hour period); and 
clinically significant cardiovascular events or disease during the 
preceding 12 months, including ongoing cardiac dysrhythmias 
of NCI CTCAE grade 2 or higher, atrial fibrillation of any grade, 
or corrected QT interval of more than 450 msec for men or more 
than 470 msec for women. Smokers were not excluded from 
cohort 1, but patients enrolled in cohort 2 were required to be 
never-smokers or exsmokers for 6 months or more. All patients 
were required to be 18 years of age or older, and those in cohort 2 
were also required to be younger than 70 years of age.
All patients gave written informed consent for their par-
ticipation in the study. The study was run in accordance with 
the International Conference on Harmonization Good Clinical 
Practice guidelines and applicable local regulatory requirements 
and laws, and was approved by the Institutional Review Board or 
Independent Ethics Committee of each participating center.
Study Design and Treatment
This study was a phase II trial that included a lead-in 
cohort to test safety and pharmacokinetics. In the original lead-
in cohort (cohort 1), patients were evaluated for dose-limiting 
toxicities (DLTs) and pharmacokinetics (assessing the effect 
of sunitinib on erlotinib), and received oral sunitinib 37.5 mg/d 
(continuous daily dose) plus erlotinib 150 mg/d in cycle 1 for 
28 days, then erlotinib alone for days 29 to 35 and for day 1 of 
cycle 2. Concomitant sunitinib plus erlotinib resumed on day 2 
of cycle 2, and treatment continued in 28-day cycles (Fig. 1A). 
The planned sample size for cohort 1 was 10 patients; if fewer 
than six patients completed full pharmacokinetic profiles, then 
subsequent patients were to be enrolled concurrently with the 
randomized part of the trial once the 10 subjects completed the 
28-day DLT observation period in cycle 1.
To obtain additional pharmacokinetic information, 
including the effect of erlotinib on sunitinib kinetics, the protocol 
was amended to include an additional lead-in cohort (cohort 2). 
Twelve patients were planned for cohort 2; six patients in arm 
A to investigate the effect of steady-state concentrations of 
sunitinib on the pharmacokinetics of erlotinib after a single dose, 
and six patients in arm B to investigate the effect of steady-state 
concentrations of erlotinib on the pharmacokinetics of sunitinib 
after a single dose. If fewer than 12 evaluable patients completed 
full pharmacokinetic sampling, cohort 2 could be expanded. 
In cycle 1, patients in arm A received erlotinib 150 mg/d alone 
on day 1, sunitinib 37.5 mg/d on days 2 to 28, with concurrent 
erlotinib administered on day 22, and days 24 to 28 only. In arm 
B, patients received sunitinib 37.5 mg/d alone on day 1, erlotinib 
150 mg/d on days 3 to 28 with concurrent sunitinib on days 15, 
and days 18 to 28. In both arms, sunitinib and erlotinib were given 
in combination for days 1 to 28 from cycle 2 onward (Fig. 1B). 
In cohort 2, current or recent smokers were excluded because 
smokers are known to have lower plasma levels of erlotinib.24
Patients in both lead-in cohorts continued to receive 
treatment after the randomized phase of the trial had started. 
The dose of erlotinib could be reduced to 100 mg/d and then to 
50 mg/d, at the investigator’s discretion. In the event of grade 
3 or higher toxicity, the dose of sunitinib could be reduced to 
25 mg/d. Treatment continued until disease progression, unac-
ceptable toxicity, or withdrawal of consent. Completion of the 
study was defined as 18 cycles of treatment.
Study Assessments
Safety and tolerability were assessed regularly through-
out the study by physical examination, hematology and 
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biochemistry tests, and urinalysis. In addition, 12-lead elec-
trocardiograms were performed at screening and in cycle 2, 
and multigated acquisition scans or echocardiograms were 
performed for cohort 2 at screening and as clinically indi-
cated, thereafter, to evaluate left ventricular ejection fraction. 
Adverse events (AEs) were monitored and graded according 
to NCI CTCAE version 3.0, and the investigators’ assess-
ment of the relationship of AEs to the study treatment was 
documented.
Patients in cohort 1 completing the first 28 days of cycle 
1 were evaluable for DLTs occurring during this period. DLTs 
were defined as the following treatment-related toxicities: 
grade 4 neutropenia lasting 7 days or more; febrile neutropenia; 
neutropenic infection; grade 3 or higher thrombocytopenia with 
bleeding; grade 4 thrombocytopenia lasting 7 days or more; 
any grade 3/4 nonhematologic toxicity lasting 7 days or more 
(except for asymptomatic hyperuricemia and hypophosphate-
mia); nausea/vomiting/diarrhea persisting at grade 3/4 despite 
optimal medical therapy; and rash requiring discontinuation of 
either drug, dose reduction of erlotinib to less than 100 mg/d 
or dose reduction of sunitinib to less than 25 mg/d. Inability to 
complete 75% or more of the sunitinib doses and 75% or more 
of the erlotinib doses was also considered a DLT. If there were 
no more than three patients with DLTs excluding dyspnea, and 
no more than four cases including dose-limiting dyspnea dur-
ing the observation period, the randomized phase of the study 
FIGURE 1.  Study schema. D, day; PK, pharmacokinetic.
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would commence. In the event of more than three DLTs exclud-
ing dyspnea (or more than four cases including dose-limiting 
dyspnea), the dose and/or schedule of either or both medica-
tions could be modified for the randomized phase.
Plasma levels of sunitinib, its active metabolite 
SU12662, and erlotinib were assayed using validated high-
performance liquid chromatography/tandem mass spectrom-
etry methods (BASi Inc., Indianapolis, IN; PPD, Richmond, 
VA). In cohort 1, blood samples for pharmacokinetic evalu-
ation of erlotinib were obtained on day 15 cycle 1 and day 1 
cycle 2, predose, and at 1, 2, 4, 6, 8, 10, and 24 hours postdose. 
Blood samples for pharmacokinetic profiling of sunitinib and 
SU12662 were obtained at day 15 of cycle 1 at the above time 
points. Predose samples were obtained on day 1 of each cycle.
In cohort 2, blood samples for erlotinib pharmacoki-
netic profiling were obtained from patients in arm A on day 
1 (without sunitinib) and day 22 of cycle 1 (with sunitinib at 
steady state) at 1, 2, 4, 6, 8, and 24 hours postdose, and suni-
tinib and SU12662 trough plasma samples were obtained on 
days 22 and 23. In arm B pharmacokinetic samples for suni-
tinib and SU12662 were collected on day 1 (without erlotinib) 
and day 15 of cycle 1 (with erlotinib at steady state) at 1, 2, 
4, 6, 8, 24, and 48 hours postdose. Erlotinib trough plasma 
concentrations were collected on days 15 to 17. Erlotinib and 
sunitinib trough samples were collected on day 1 of cycles 2 
to 13. Trough samples collected on day 1 of cycle 2 were not 
considered true troughs as both sunitinib and erlotinib were 
not given concomitantly for long enough to achieve steady-
state concentrations of both medications.
Tumor response was evaluated by computed tomography 
or magnetic resonance imaging performed at baseline, dur-
ing treatment (cohort 1: cycles 2–4 and even-numbered cycles 
thereafter; cohort 2: cycle 2, 3, and odd-numbered cycles there-
after), and at the end of treatment, to confirm a response or if 
disease progression was suspected. Bone scans were performed 
at screening and repeated when tumor imaging was performed 
if bone metastases were identified or suspected. Objective tumor 
response was based on investigators’ assessments of tumor data 
using Response Evaluation Criteria in Solid Tumors (RECIST). 
Brain scans were performed at screening to exclude brain dis-
ease and repeated if brain disease was suspected.
Statistics
All patients received at least one dose of study medica-
tion and were included in the analyses. Descriptive statistics 
were used to summarize safety, efficacy, and pharmacokinetic 
variables including maximum plasma concentration (C
max
), 
time for C
max
 (T
max
), area under plasma concentration–time 
profile from time 0 to 24 hours (AUC
0–24
), and clearance after 
oral administration. C
max
 and AUC
0–24
 were analyzed after nat-
ural log transformation using a one-way analysis of variance. 
Mean values and 90% confidence intervals obtained from the 
model were back-transformed. The effect of coadministra-
tion of erlotinib on the pharmacokinetics of sunitinib and the 
effect of coadministration of sunitinib on the pharmacokinet-
ics of erlotinib were explored and 90% confidence intervals 
for the ratio of geometric means between collection days are 
presented.
RESULTS
Patients and Study Treatment
Overall, 30 patients were enrolled: 13 to cohort 1 and 17 
to cohort 2. These cohorts were larger than planned because 
some patients did not provide full pharmacokinetic profiles 
and, in cohort 2, there was an attempt to balance arms A and B 
by sex, which resulted in additional patients being recruited. 
The overall median age was 64 years (range, 43–75), and the 
majority of patients were current or exsmokers (73.3%). All 
subjects in cohort 2 were nonsmokers or exsmokers for at 
least 6 months, except two who were enrolled in violation of 
protocol. One of these patients had stopped smoking 3 months 
before screening, and so was classified as a current smoker 
as per protocol criteria, which stipulated 6 months. One of 
the primary objectives of cohort 2 was to determine whether 
erlotinib affects the pharmacokinetics of sunitinib. Because 
smoking can decrease blood levels of erlotinib, nonsmokers 
were chosen for cohort 2 to avoid the possibility of confound-
ing results from patients who smoked during the first set of 
pharmacokinetic samples but quit smoking before the second 
set of samples. In addition, smokers were excluded because 
their lower erlotinib exposure could limit the ability to detect 
an interaction. The recommended phase II dose was based on 
the safety evaluation in cohort 1 that included smokers and 
nonsmokers.
Most patients had adenocarcinoma (70%), and all had 
stage IV disease (Table 1). Seven patients in cohort 1 provided 
tumor tissue for analysis; for EGFR, two were confirmed as 
wild type and five were indeterminate. For KRAS, one was 
wild type, one was mutated, and five were indeterminate. No 
tissue samples were available from cohort 2.
At the time of analysis, treatment was ongoing in two 
patients from cohort 2, and one patient had completed the 
study as per protocol (i.e., received 18 cycles of treatment). All 
other patients discontinued study treatment because of disease 
progression (n = 17, 56.7%); death (n = 1, 3.3%, because of 
disease progression); AE (n = 6, 20.0%, [n = 1 each of grade 
4 pulmonary embolism], grade 3 fatigue, grade 3 dyspnea, 
grade 2 dehydration/grade 4 staphylococcal pneumonia/grade 
4 abdominal pain, grade 5 respiratory failure, and fatigue/
peripheral edema/dyspnea, all grade 2); and withdrawal of 
consent (n = 3; 10.0%).
Across both lead-in cohorts, patients started a median 
of 2.5 treatment cycles (range, 1–18, Table 2). Median relative 
dose intensity was 90.0% for sunitinib and 92.5% for erlotinib. 
In total, 10.0% and 26.7% of patients experienced at least one 
dose delay and at least one dose reduction of sunitinib, respec-
tively, and 6.7% and 36.7% of patients experienced at least 
one dose delay and at least one dose reduction of erlotinib, 
respectively (Table 2).
Safety
In cohort 1, the most common all-causality AEs were 
diarrhea (76.9%), fatigue (61.5%), decreased appetite 
(53.8%), acne (46.2%), cough (46.2%), and rash (46.2%; 
Table 3), with the most common grade 3/4 events being diar-
rhea (five [38.5%] grade 3 events), and dyspnea (two [15.4%] 
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TABLE 1. Baseline Patient Characteristics
Characteristics
Cohort 1 
(n = 13)
Cohort 2 
(n = 17)
Total 
(N = 30)
Median age, yrs 
(range)
64 (47–75) 64 (43–69) 64 (43–75)
Men/women, n (%) 7/6 (53.8/46.2) 11/6 (64.7/35.3) 18/12 (60.0/40.0)
ECOG performance status, n (%)
 0 2 (15.4) 8 (47.1) 10 (33.3)
 1 11 (84.6) 9 (52.9) 20 (66.7)
Smoking status, n (%)
 Never smokera 4 (30.8) 4 (23.5) 8 (26.7)
 Current smoker 2 (15.4) 2 (11.8) 4 (13.3)
 Exsmokera 7 (53.8) 11 (64.7) 18 (60.0)
Race, n (%)
 White 12 (92.3) 16 (94.1) 28 (93.3)
 Black/other 1 (7.7) 1 (5.9) 2 (6.6)
Histology, n (%)
 Adenocarcinoma 11 (84.6) 10 (58.8) 21 (70.0)
 Squamous cell 
carcinoma
2 (15.4) 6 (35.3) 8 (26.7)
 Large cell 0 1 (5.9) 1 (3.3)
Stage IV disease, n (%) 13 (100.0) 17 (100.0) 30 (100.0)
Disease site, n (%)b
 Lungs 11 (84.6) 13 (76.4) 24 (80.0)
 Lymph node, 
regional
6 (46.2) 9 (52.9) 15 (50.0)
 Bone 7 (53.8) 3 (17.6) 10 (33.3)
 Lymph node, 
distant
3 (23.1) 4 (23.5) 7 (23.3)
 Liver 1 (7.7) 6 (35.3) 7 (23.3)
 Mediastinum 1 (7.7) 6 (35.3) 7 (23.3)
 Other 3 (23.1) 9 (52.9) 12 (40.0)
Months since initial 
diagnosis, median 
(range)
11.8 (2, 53) 9.9 (0, 87) 11.3 (0, 87)
Prior surgeries, n (%)
 None 0 4 (23.5) 4 (13.3)
 Resected/partially  
resected
5 (38.5) 3 (17.6) 8 (26.7)
 Otherc 12 (92.3) 12 (70.6) 24 (80.0)
Prior radiation therapy, n (%)
 None 8 (61.5) 11 (64.7) 19 (63.6)
 Adjuvant 2 (15.4) 1 (5.9) 3 (10.0)
 Advanced/ 
metastatic
3 (23.1) 5 (29.4) 8 (26.7)
Prior chemotherapy regimens, n (%)
  1 8 (61.5) 12 (70.6) 20 (66.7)
  2 4 (30.8) 4 (23.5) 8 (26.7)
  ≥3d 1 (7.7) 1 (5.9) 2 (6.7)
Progressive disease  
at study entrye
13 (100.0) 17 (100.0) 30 (100.0)
a Never smokers were defined as those whose lifetime number of cigarettes was <100. 
Exsmokers were defined as those who had quit smoking at least 6 months before study entry.
 bIncluded both target and nontarget sites; each patient could have multiple disease 
sites. “Other” includes adrenal, pericardial effusion, pleural effusion, kidney, chest wall, 
and pleura.
cIncludes biopsy, unresected and not found.
dRepresents a protocol violation (>2 prior chemotherapy regimens).
eOn the basis of investigator assessment of best overall response to a prior chemo-
therapy regimen, or progression identified on prior radiographic imaging.
ECOG, Eastern Cooperative Oncology Group.
TABLE 2. Exposure to Sunitinib and Erlotinib by Cohort
Cohort 1 
(n = 13)
Cohort 2 
(n = 17)
Total 
(N = 30)
Sunitinib exposure
 Median number of cycles 
started (range)
2 (1–18) 3 (1–11) 2.5 (1–18)
 Median days on treatment 
(range)
49 (6–662) 71 (13–297) 66.5 (6–662)
 Patients with ≥1 dose delaya, 
n (%)
1 (7.7) 2 (11.8) 3 (10.0)
 Reason for dose delay, n (%)
  Adverse event 0 2 (11.8) 2 (6.7)
  Both adverse event and other 1 (7.7) 0 1 (3.3)
 Patients with ≥1 dose 
interruptionb, n (%)
5 (38.5) 5 (29.4) 10 (33.3)
 Reason for dose interruption, 
n (%)
  Adverse event 4 (30.8) 4 (23.5) 8 (26.7)
  Both adverse event and other 1 (7.7) 1 (5.9) 8 (26.7)
 Patients with ≥1 dose 
reductionc, n (%)
4 (30.8) 4 (23.5 8 (26.7)
 Reason for dose reduction, n (%)
  Adverse event 3 (23.1) 3 (18) 6 (20)
  Both adverse event and other 1 (7.7) 1 (5.9) 2 (6.7)
Erlotinib exposure
 Median number of cycles 
started (range)
2 (1–18) 3 (1–11) 2.5 (1–18)
 Median days on treatment 
(range)
49 (6–622) 69 (14–295) 65.5 (6–622)
 Patients with ≥1 dose delaya, 
n (%)
1 (7.7) 1 (5.9) 2 (6.7)
 Reason for dose delay, n (%)
  Adverse event 0 1 (5.9) 1 (3.3)
  Both adverse event and other 1 (7.7) 0 1 (3.3)
 Patients with ≥1 dose 
interruptionb, n (%)
6 (46.2) 6 (35.3) 12 (40.0)
 Reason for dose interruption, 
n (%)
  Adverse event 5 (38.5) 5 (29.4) 10 (33.3)
  Both adverse event and other 1 (7.7) 1 (5.9) 2 (6.7)
 Patients with ≥1 dose 
reductionc, n (%)
5 (38.5) 6 (35.3) 11 (36.7)
 Reason for dose reduction, n (%)
  Adverse event 4 (30.8) 4 (23.5) 8 (26.7)
  Both adverse event and other 1 (7.7) 2 (11.8) 3 (10.0)
a Defined as a delay of ≥4 days in starting the next cycle.
b Defined as any missed doses in the middle of a cycle.
c Dose reduction to 25 mg/d for sunitinib or to 100 mg/d for erlotinib.
grade 3 and one [7.7%] grade 4 events). Two grade 3 events 
(15.4%) of both fatigue and anemia were also reported. In 
cohort 2, the most common all-causality AEs were diarrhea 
(52.9%) and rash (41.2%; Table 3), with the most common 
grade 3/4 AEs being diarrhea (two grade 3 events), abdominal 
pain (one grade 3 and one grade 4 event), and skin toxicity 
(two grade 3 events).
Diarrhea was the most common event considered 
related to either sunitinib and/or erlotinib treatment, occurring 
in 10 patients (76.9%) in cohort 1 and nine patients (52.9%) 
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in cohort 2. This included seven patients with grade 3 diar-
rhea across both cohorts (no grade 4 diarrhea was reported). 
All cases of fatigue (61.5%, n = 2 grade 3), acne (46.2%, 
n = 1 grade 3), and rash (46.2%, all grade ≤ 2) were considered 
treatment related in cohort 1, as were almost all cases of rash 
(35.3%, all grade ≤ 2) in cohort 2. Treatment-related hemato-
logic events were relatively infrequent, with the most common 
being neutropenia (three patients in cohort 1, all grade ≤ 2).
Only cohort 1 was designed for the evaluation of DLTs 
to establish the safety of this combination. Three subjects in 
this cohort experienced DLTs during cycle 1 (n = 2 grade 3 
fatigue, n = 1 grade 3 paronychial inflammation). None of the 
DLTs were considered serious adverse events (SAEs).
SAEs (all causality) were experienced by approximately 
40% of subjects in each cohort. The SAEs reported for more 
than one patient were disease progression (one and two sub-
jects in cohorts 1 and 2, respectively), dyspnea (two subjects in 
cohort 1), and respiratory failure (one subject in each cohort). 
There were three treatment-related SAEs in cohort 1 (grade 3 
dyspnea, grade 3 gastroenteritis, and grade 4 pulmonary embo-
lism), and five in cohort 2 (grade 3 diarrhea, grade 4 dehydra-
tion, grade 4 abdominal pain, grade 4 asthenia, and grade 2 
epistaxis). Although one case of fatal necrotizing pancreatitis 
has been previously reported in a patient with NSCLC receiving 
erlotinib plus sunitinib,25 there was no evidence of pancreatitis 
reported for the patient with grade 4 abdominal pain in this study. 
This patient had a history of gall bladder disease and developed 
abdominal pain 3 weeks after study drug discontinuation.
Three patients (23.1%) in cohort 1 and two patients (11.8%) 
in cohort 2 reported AEs that led to reductions in the dose of 
sunitinib. Four patients (30.8%) in cohort 1 and three patients 
(17.6%) in cohort 2 reported AEs associated with reductions 
in the dose of erlotinib. In addition to the 6 patients described 
previously who discontinued study treatment because of AEs, 
two other patients who discontinued the study treatment because 
of disease progression were also documented as having grade 2 
fatigue and grade 3 diarrhea as other reasons for discontinuation.
Across both lead-in cohorts, cardiac failure and thyroid 
dysfunction were not reported. Hypertension was observed in 
5 patients (16.7%), including 3 events (n = 1 grade 4) that 
were considered treatment related. Bleeding complications 
were reported in 3 patients (10.0%), two were events of grade 
2 hemoptysis (one patient with squamous cell histology and 
the other with adenocarcinoma histology; n = 1 considered 
treatment related) and one event of grade 1 pulmonary hemor-
rhage in a patient with squamous cell histology.
There were six deaths on-study; none were considered 
related to treatment toxicity (n = 3 disease progression, n = 2 
respiratory failure, and n = 1 dilated cardiomyopathy, occurring in 
a 67-year-old man 3 days after his last dose of study medication).
Pharmacokinetics
Sunitinib
Pharmacokinetic parameters for sunitinib, SU12662, 
and total drug (sunitinib plus SU12662) after administration 
of sunitinib either alone or in combination with erlotinib are 
summarized in Table 4. In cohort 1, the ratios for C
max
 and for 
AUC
0–24
 (when sunitinib and erlotinib were at steady state) rela-
tive to historical data when sunitinib was at steady state but in 
the absence of erlotinib, samples from a study of patients with 
TABLE 3. All Causality Treatment-Emergent AEs ( ≥10% of 
Patients in Either Cohort)
Cohort 1 
(n = 13), n (%)
Cohort 2 
(n = 17), n (%)
All  
Grades Grades 3/4
All  
Grades Grades 3/4
Diarrhea 10 (76.9) 5 (38.5)/0 9 (52.9) 2 (11.8)/0
Fatigue 8 (61.5) 2 (15.4)/0 2 (11.8) 0
Decreased appetite 7 (53.8) 1 (7.7)/0 1 (5.9) 0
Acne 6 (46.2) 1 (7.7)/0 0 0
Cough 6 (46.2) 1 (7.7)/0 2 (11.8) 0
Rash 6 (46.2) 0 7 (41.2) 0
Dehydration 5 (38.5) 1 (7.7)/0 2 (11.8) 0/1 (5.9)
Dyspnea 5 (38.5) 2 (15.4)/1 (7.7) 3 (17.6) 0
Nausea 5 (38.5) 1 (7.7)/0 1 (5.9) 0
Anemia 4 (30.8) 2 (15.4)/0 1 (5.9) 0
Dysgeusia 4 (30.8) 0 1 (5.9) 0
Pyrexia 4 (30.8) 0 1 (5.9) 0
Arthralgia 3 (23.1) 0 0 0
Asthenia 3 (23.1) 0/1 (7.7) 1 (5.9) 0/1 (5.9)
Hypomagnesemia 3 (23.1) 0 0 0
Neutropenia 3 (23.1) 0 0 0
Vomiting 3 (23.1) 1 (7.7)/0 2 (11.8) 1 (5.9)/0
Abdominal pain 2 (15.4) 0 2 (11.8) 1 (5.9)/1 (5.9)
Blood creatinine 
increased
2 (15.4) 1 (7.7)/0 0 0
Chest discomfort 2 (15.4) 0 0 0
Dizziness 2 (15.4) 0 0 0
Dyspnea exertional 2 (15.4) 0 1 (5.9) 1 (5.9)/0
Edema peripheral 2 (15.4) 0 1 (5.9) 0
Hemorrhoids 2 (15.4) 0 0 0
Hypokalemia 2 (15.4) 0 1 (5.9) 1 (5.9)/0
Infection 2 (15.4) 0 0 0
Musculoskeletal  
chest pain
2 (15.4) 0 0 0
Oral pain 2 (15.4) 0 0 0
Oropharyngeal pain 2 (15.4) 0 0 0
Paronychia 2 (15.4) 1 (7.7)/0 0 0
Stomatitis 2 (15.4) 0 0 0
Thrombocytopenia 2 (15.4) 0/1 (7.7) 0 0
Urinary tract  
infection
2 (15.4) 0 1 (5.9) 0
White blood cell  
count decreased
2 (15.4) 0 0 0
Abdominal pain  
upper
1 (7.7) 0 3 (17.6) 0
Dermatitis  
acneiform
1 (7.7) 0 3 (17.6) 0
Disease progression 1 (7.7) 0 2 (11.8) 0
Epistaxis 1 (7.7) 0 2 (11.8) 0
Hypertension 1 (7.7) 0 4 (23.5) 0/1 (5.9)
Hemoptysis 0 0 2 (11.8) 0
Skin toxicity 0 0 3 (17.6) 2 (11.8)/0
AEs, adverse events.
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advanced solid malignancies, 26 collected after 15 days of dos-
ing of sunitinib at 37.5 mg/d (n = 12) were 0.77 and 0.62 for 
sunitinib, 1.67 and 1.46 for SU12662, and 1.03 and 0.86 for 
total drug. Similarly, in cohort 2 arm B, the geometric mean 
ratios for C
max
 and AUC
0–24
 were 0.62 and 0.62 for sunitinib, 
2.13 and 2.07 for SU12662, and 0.81 and 0.79 for total drug.
Erlotinib
Pharmacokinetic parameters for erlotinib are summa-
rized in Table 5. For cohort 1 historical data from study BR.21 
(a randomized, double-blind, placebo-controlled phase III 
study, in which 731 patients with NSCLC received erlotinib 
[150 mg/d] or placebo) were used because there were paired 
observations for only two patients.8 In cohort 1, the mean val-
ues for C
max
 (2.4 µg/ml) and AUC
0–24
 (37.7 µg/hr per millili-
ter) for erlotinib when combined with sunitinib were similar 
to historical control data for erlotinib alone (C
max
: 2.0 ng/ml, 
AUC
0–24
: 41.3 µg/hr/ per milliliter).8 In cohort 2 arm A, the 
ratios of the geometric means for C
max
 and for AUC
0–24
 (in the 
erlotinib plus sunitinib arm relative to the erlotinib arm) were 
1.05 and 1.03, respectively. These values exclude one patient 
considered an outlier as a result of incomplete absorption 
for unknown reasons during the sampling period (T
max
 was 
observed 24 hours postdose, just before dose administration 
the following day). Concentration-time profiles for sunitinib, 
SU12662, total drug, and erlotinib are presented in Figure 2.
Antitumor Efficacy
Three patients experienced partial response; no com-
plete response was observed. All the patients with partial 
response were exsmokers, and include a 59-year-old black 
woman with adenocarcinoma (duration of response 617 days) 
who had received one prior chemotherapy regimen (carbo-
platin/paclitaxel), a 54-year-old white man with squamous 
cell carcinoma (duration of response 109 days ) who had 
received two prior chemotherapy regimens (irinotecan/cis-
platin/carboplatin/paclitaxel, and carboplatin/gemcitabine), 
and a 65-year-old white man with squamous cell carcinoma 
(duration of response ≥155 days ) who had received two 
TABLE 4.  Pharmacokinetic Parameters for Sunitinib, SU12662, and Total Drug
Parameter  
(n = 8 for All Groups)
Mean (%CV) [Median] 
Sunitinib Alone
Mean (%CV) [Median] 
Erlotinib + Sunitinib
Geometric Mean Ratio (90% CI) 
[Combination/Sunitinib Alone]
Cohort 1, n = 8 (sunitinib and erlotinib at steady state, C1 D15)
 Sunitinib
  T
max
 (hr)a 6.0 (1.0–10.0)b 7.0 (4.0–10.0) NA
  C
max
 (ng/ml) 51.1 (39) [44.3]b 38.4 (29) [39.3] 0.77
  AUC
24
 (ng/hr per milliliter) 1056 (41) [970]b 619 (23) [628] 0.62
  CL/F (liter/hr) 40.8 (37) [38.8]b 63.3 (21) [59.8] 1.62
 SU12662
  T
max
 (hr)a 6.0 (2.0–24.0)b 7.0 (4.0–24.0) NA
  C
max
 (ng/ml) 18.8 (41) [17.3]b 31.2 (35) [32.7] 1.67
  AUC
24
 (ng/hr per milliliter) 403 (39) [375]b 575 (30) [593] 1.46
 Total Drug
  T
max
 (hr)a 6.0 (1.0–10.0)b 7.0 (4.0–10.0) NA
  C
max
 (ng/ml) 69.0 (37) [59.3]b 69.5 (26) [62.8] 1.03
  AUC
24
 (ng/hr per milliliter) 1460 (36) [1341]b 1194 (16) [1254] 0.86
Cohort 2 arm B, n = 8 (single-dose sunitinib, erlotinib at steady state)
 Sunitinib (n = 8) C1 D1 C1 D15
  T
max
 (hr)a 6.0 (4.0–8.0) 6.0 (4.0–24.0) NA
  C
max
 (ng/ml) 21.6 (31) [23] 13.6 (43) [12.1] 0.62 [0.44, 0.86]
  AUC
24
 (ng/hr per milliliter) 373 (28) [397] 232 (30) [222] 0.62 [0.48, 0.81]
SU12662 (n = 8)
  T
max
 (hr)a 4.0 (2.0–48.0) 4.0 (4.0–8.0) NA
  C
max
 (ng/ml) 3.09 (43) [3.28] 6.83 (62) [5.29] 2.13 [1.31, 3.46]
  AUC
24
 (ng/hr per milliliter) 50.1 (45) [47.1] 99.6 (40) [84.6] 2.07 [1.39, 3.08]
 Total drug (n = 8)
  T
max
 (hr)a 6.0 (4.0–8.0) 5.0 (4.0–24.0) NA
  C
max
 (ng/ml) 24.5 (31) [25.3] 20.1 (39) [18.6] 0.81 [0.58, 1.13]
  AUC
24
 (ng/hr per milliliter) 423 (29) [445] 331 (27) [327] 0.79 [0.61, 1.04]
a T
max
: median (min, max)
b Historical controls from study A618108425 (sunitinib [37.5 mg/d on a continuous daily dose schedule] alone on cycle 1 day 15 in patients with advanced solid malignances; n = 12)  
sunitinib plasma samples in cohort 1 were only collected when sunitinib was coadministered with erlotinib.
AUC
24
, area under plasma concentration–time profile at 24 hours; C, cycle; CI, confidence interval; CL/F,clearance after oral administration; C
max
, maximum plasma concentra-
tion; CV, coefficient of variation; D, day; NA, not applicable; Total drug, sunitinib + SU12662.
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prior chemotherapy regimens (carboplatin/vinorelbine and 
carboplatin/gemcitabine).
DISCUSSION
Patients with advanced NSCLC inevitably experi-
ence disease progression after first-line therapy, and further 
treatment options are limited. Second-line pemetrexed can 
modestly improve survival in patients with nonsquamous 
histology,27 and erlotinib is approved for advanced NSCLC 
regardless of histologic diagnosis based on a survival ben-
efit of approximately 2 months in both squamous and non-
squamous disease relative to histology-matched controls who 
received placebo in the BR.21 trial.8 Nevertheless, there is a 
clear unmet need for more treatment options in the refractory 
setting. Combining targeted inhibition of VEGFR, PDGFR, 
and EGFR in advanced NSCLC is a rational approach based 
on the overlapping and complementary antiangiogenic and 
antitumor effects of inhibiting these RTK pathways.19–21
In these two lead-in cohorts, the combination of 
sunitinib 37.5 mg/d plus erlotinib 150 mg/d was tolerable, 
and the observed toxicity profile was consistent with those 
previously reported in NSCLC trials of single-agent sunitinib 
or erlotinib.8,16,17,28 Although the treatment was tolerable, AEs 
were frequent; each patient in cohort 1 experienced an AE 
considered related to treatment, along with 76.5% of patients 
in cohort 2. The higher frequency of AEs reported in cohort 1 
may reflect the longer duration of treatment received by some 
patients (up to 622 days) compared with the duration in cohort 
2 (up to 297 days, Table 2). The most common AE attributed 
to sunitinib and/or erlotinib treatment was diarrhea, a known 
effect of both agents. In most patients, it was managed with 
standard antidiarrheal treatments. Fifteen patients received 
antidiarrheals, 11 of whom received loperamide, seven 
received diphenoxylate and atropine, and one each received 
antidiarrheal microorganisms, activated charcoal, and tincture 
of opium. Treatment-related AEs of fatigue, acne, and rash 
were also common in cohort 1, and rash (35.3%) was also 
reported in cohort 2. We recommend that rash be treated 
with a topical cream and emollients and/or antibiotics as 
would typically be done for a patient receiving erlotinib. 
These toxicities are consistent with those reported from from 
single-agent studies of both agents.8,16,17 However, in a recent 
single-institution phase I study of sunitinib plus erlotinib on a 
continuous daily dose schedule in 11 patients with advanced 
nonsquamous NSCLC, the regimen was poorly tolerated 
with rates of grade 3 diarrhea and mucositis higher than that 
expected for either agent alone.29 In the current study, three 
DLTs were observed in cohort 1: two cases of grade 3 fatigue 
(a toxicity known to be associated with sunitinib and erlotinib 
and the disease itself) and one case of grade 3 paronychial 
inflammation, an AE previously documented in trials of 
erlotinib and associated rarely with sunitinib.30,31 As per the 
study protocol, based on the observed DLTs, recruitment into 
the randomized phase of this trial proceeded at the doses of 
sunitinib and erlotinib described above.
Two cases of grade 2 hemoptysis were reported (one 
of which was in a patient with squamous cell histology) and 
one case of grade 1 pulmonary hemorrhage was reported in a 
patient with squamous cell histology. In other trials, bleeding 
complications have alsooccurred disproportionately in patients 
with a squamous NSCLC who received sunitinib or other 
antiangiogenic agents, aside from bevacizumab. At the time 
this study was conducted, there were reports of hemoptysis 
with bevacizumab in patients with squamous cell carcinoma, 
but the degree of risk was unclear. Nevertheless, because a 
TABLE 5.  Pharmacokinetic Parameters for Erlotinib
Cohort, Parameter
Mean (%CV) [Median] 
Erlotinib Alone
Mean (%CV) [Median] 
Erlotinib + Sunitinib
Geometric Mean Ratio [90% CI] 
(Combination/Erlotinib Alone)
Cohort 1, n = 8 (sunitinib and erlotinib at steady state, C1 D15)
 T
max
 (hr)a NR 3.0 (1.0–8.0) NA
 C
max
 (µg/ml) 2.0 ± 0.91b 2.40 (51) [2.35] NC
 AUC
0–24
 (µg/hr per milliliter) 41.3 ± 22b 37.7 (58) [30.5] NC
 CL/F (liter/hr) 3.95b 5.52 (66) [4.92] NC
Cohort 1, n = 2c (sunitinib and erlotinib at steady state, C1 D15)
 T
max
 (hr)a 4.0 (2.0–6.0) 2.0 (2.0–2.0) NA
 C
max
 (µg/ml) 1.81 (60) [1.81] 2.11 (66) [2.11] 1.14 [0.16, 8.34]
 AUC
0–24
 (µg/hr per milliliter) 24.4 (24) [24.4] 34.7 (59) [34.7] 1.31 [0.33, 5.29]
 CL/F (liter/hr) 6.33 (24) [6.33] 5.23 (59) [5.23] 0.76 [0.19, 3.07]
Cohort 2 arm A, n = 6c,d (single-dose erlotinib, sunitinib at steady-state C1 D1 and C1 D22)
 T
max
 (hr)a 3.0 (1.0–6.0) 2.0 (1.0–6.0) NA
 C
max
 (µg/ml) 0.99 (53) [0.70] 0.97 (24) [0.94] 1.05 [0.72, 1.53]
 AUC
0–24
 (µg/hr per milliliter) 13.2 (33) [12.4] 13.3 (19) [13.4] 1.03 [0.78, 1.35]
a T
max
: median (min, max).
b Historical controls from study BR.21 (a randomized, double-blind, placebo-controlled phase III trial. Patients with NSCLC received erlotinib [150 mg/d] or placebo; mean ± 
standard error of mean reported)8 as there were paired observations for only n = 2 in cohort 1.
c Patients with paired observations only.
d Excluding the outlying patient with incomplete absorption for unknown reasons.
AUC
0–24
, area under plasma concentration–time profile from time 0–24 hours; C, cycle; CL/F, clearance after oral administration; CV, coefficient of variation; C
max
, maximum 
plasma concentration; D, day; NA, not applicable; NC, no change; NR, not recorded; NSCLC, non–small-cell lung cancer; T
max
, time for C
max
.
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potential risk was known, and entry criteria excluded those 
with hemoptysis (who were considered at greater risk), such 
patients were enrolled into the phase II part of this trial with 
careful monitoring for hemoptysis.
The pharmacokinetic parameters for sunitinib seemed 
to be altered by coadministration with erlotinib. In cohort 1, 
with sunitinib and erlotinib at steady state, exposure to suni-
tinib decreased whereas exposure to its metabolite SU12662, 
increased compared with historical data, when sunitinib was 
dosed daily as a single agent. Similar findings were observed 
in cohort 2. In arm B of this cohort (single-dose sunitinib with 
erlotinib at steady state), increased exposure to sunitinib’s 
active metabolite SU12662 was again observed. An approxi-
mate 20% reduction in exposure to total drug was also noted. 
These observations suggest that erlotinib increases the metab-
olism of sunitinib, likely via CYP3A4 isoenzyme induction. 
FIGURE 2.  Sunitinib, SU12662, total drug, and erlotinib mean plasma concentration versus time profiles. A, Cohort 1 (suni-
tinib and erlotinib at steady state). B, Cohort 2 (potentially interacting drug at steady state). Cohort 1: Sunitinib and erlotinib 
at steady state (cycle 1, day 15); erlotinib at steady state with 7 days washout for sunitinib (cycle 2, day 1). Cohort 2: sunitinib 
alone (arm B, cycle 1, day 1); sunitinib as a single dose with erlotinib at steady state (cycle 1, day 15); erlotinib alone (arm A, 
cycle 1, day 1); erlotinib as a single dose with sunitinib at steady state (arm A, cycle 1 day 22). SS, steady state.
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Erlotinib has been reported to act as an inducer that influences 
the metabolism of other CYP3A4 substrates.30 For example, it 
increases the metabolism of midazolam and the formation rate 
of 1′-hydroxymidazolam in vitro.32
In contrast, the pharmacokinetics of erlotinib seemed 
relatively unaffected by coadministration of sunitinib. In 
cohort 1, pharmacokinetic parameters for erlotinib were com-
parable with historical control data of single-agent erlotinib 
from the phase III trial, BR.218 (geometric mean ratio values 
with the observed data in cohort 1 were generated for only the 
2 patients who had paired observations). In cohort 2 arm A 
(single-dose erlotinib, sunitinib at steady state), pharmacoki-
netic parameters for erlotinib during single administration and 
coadministration with sunitinib were very similar (geometric 
mean ratios for sunitinib plus erlotinib relative to erlotinib 
alone [C
max
 of 1.05 and AUC
0–24
 of 1.03]).
Across both cohorts, three PRs provided preliminary 
evidence of antitumor activity, although clinical efficacy was 
not the primary focus of the lead-in population of this study. 
The randomized phase II portion of this study has been com-
pleted33 and full data will be reported separately.
In summary, although formal maximum tolerated dose 
was not assessed, data from the lead-in cohorts of a phase II 
trial investigating sunitinib 37.5 mg/d plus erlotinib 150 mg/d 
in patients with refractory NSCLC suggest that the treatment 
combination is tolerable, with a toxicity profile consistent with 
that established for each individual drug. Pharmacokinetic eval-
uations indicate that coadministration of sunitinib and erlotinib 
results in decreased exposure to sunitinib while erlotinib expo-
sure is unaffected. The changes in total drug (sunitinib plus 
SU12662) exposure were approximately 20%, which may be 
clinically relevant. Houk et al.34 demonstrated a direct correla-
tion between sunitinib exposure and efficacy. However, in this 
specific scenario, although there was a decrease in sunitinib 
exposure, exposure to the metabolite increased considerably. 
SU12662 has shown similar activity to that of the parent com-
pound, which may compensate for the reduction in sunitinib 
exposure, achieving a similar pharmacodynamic response. 
No exposure–response relationships have been explored for 
SU12662 to date. Therefore, to fully understand the clinical 
impact of this sunitinib–erlotinib interaction, further pharma-
cokinetic and pharmacodynamic analyses are required. The 
lead-in cohorts confirmed the safety of this combination for 
phase II testing, and the phase II portion of this trial proceeded 
using these doses and will be reported separately.
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